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xperimental and animal models suggest that oxidative stress, which is characterized by excessive production of reactive oxygen species and reduction of antioxidant defense capacity, may play an important role in the pathophysiology of heart failure (HF). 1 Many animal studies have demonstrated therapeutic effects of antioxidants on progression of HF. 1, 2 Consequently, antioxidant therapy has been identified as a promising intervention to attenuate the oxidative damage to prevent disease progression to HF. Dietary antioxidants, in particular vitamin C and E, which are considered important antioxidants in humans, 3, 4 have attracted particular interest. These antioxidants are thought to protect against oxidative stress by reducing levels of free oxygen radicals and inhibiting low density lipoprotein oxidation and oxidative cell damage. 4 In addition to its antioxidant properties, vitamin C also plays a role in immune function. Higher vitamin C levels are associated with lower levels of inflammatory markers and improved endothelial function. 5 In contrast to the extensive research on vitamins C and E and risk of coronary heart disease (CHD) and cardiovascular disease (CVD), 6, 7 less is known about the associations between antioxidant levels and intakes and risks of HF in the general population. Although a number of studies have investigated the role of antioxidants in patients with HF, 8, 9 studies on the association between vitamin C and E and the development of HF risk in the general population are limited, and the few trials of antioxidant supplementation in HF have been disappointing. Although 2 studies reported no association between vitamin E supplements and HF in a primary prevention population, 6 ,10 2 secondary trial studies reported increased risk of HF with vitamin E supplements in those with CVD, 11, 12 raising concern about the use of vitamin E supplements. However, we are not aware of any trials that have examined vitamin C in relation to HF specifically in a healthy population. The main source of vitamin C in humans is fruits and vegetables, and some, [13] [14] [15] but not all, studies 16, 17 have suggested that a diet high in fruit and vegetable and, thus, rich in antioxidants is associated with reduced risk of HF. Moreover, only 1 study to date has examined the association between plasma vitamin C and incident HF, which suggested that elevated plasma vitamin C was associated with reduced risk of HF. 17 We have examined the association between plasma vitamin C and E as well as dietary intake of vitamin C and E (α-tocopherol) in relation to incident HF in men with and without pre-existing MI free of HF at baseline and examined possible mediating factors.
Methods
The British Regional Heart Study is a prospective study involving 7735 men aged 40 to 59 years drawn from a general practice in each of 24 British towns, who were screened between 1978 and 1980. 18 The population studied was socioeconomically representative of British men and comprises predominantly white Europeans (>99%). In 1998 to 2000, all available surviving men, then aged 60 to 79 years, were invited for a 20th year follow-up examination. Ethical approval was obtained from all relevant local research ethics committees. All men gave informed consent and completed a mailed questionnaire providing information on their lifestyle and medical history, had a physical examination, and provided a fasting blood sample. The samples were frozen and stored at −20 o C on the day of collection and transferred in batches for storage at −70 o C until analysis, performed after no >1 freeze-thaw cycle. Twelve lead electrocardiograms were recorded using a Siemens Sicard 460 instrument and were analyzed using Minnesota Coding definitions at the University of Glasgow. The men were asked whether a doctor had ever told them that they had angina or myocardial infarction (MI), HF, or stroke; details of their medications, including use of aspirin and statins, were recorded at the examination. The present report is based on the 4252 men (77% of available survivors) who attended the 1998 to 2000 examination (Figure in the online-only Data Supplement); 4036 men had measurements of either plasma vitamin C or E, or both. Of these men, we excluded 117 men with prevalent HF, leaving 3919 men for analysis.
Cardiovascular Risk Factor Measurements at 20-Year Examination (1998-2000)
Details of measurement and classification methods for body mass index, smoking status, physical activity, social class, alcohol intake, blood pressure, blood lipids, and forced expiratory volume in 1 second (FEV 1 ) in this cohort have been described. 19, 20 C-reactive protein (CRP) was assayed by ultrasensitive nephelometry (Dade Behring, Milton Keynes, UK). Predicted glomerular filtration rate (measure of renal function) was estimated from serum creatinine using the equation, estimated glomerular filtration rate=1 86×(creatinine) − 
Dietary and Plasma Vitamin C and E at 20-Year Examination
Dietary intake was obtained from a detailed 7-day recall food frequency questionnaire that was developed for use in the World Health Organization MONICA (MONItoring trends and determinants in CArdiovascular disease) survey and later for the Scottish Heart Health Study, 22 and was validated against weighed intake in both a Welsh 23 and a Scottish population 24 and against plasma vitamin C levels. 22 Study participants were asked to recall their usual intake during the past 7 days by reporting amounts and frequency of food consumed, which included 86 different food and drinks. Nutrient intakes were calculated using a validated program that multiplied the food frequency by the standard portion sizes for each food and by the nutrient composition of the foods obtained from the UK food composition tables. 25 They were additionally asked whether they regularly took any vitamins or mineral tablets. Information on the dose amount of vitamin C taken in supplements was not available. Supplement use of vitamin C or vitamin E was not included in the calculation of dietary vitamin C/E intake. Plasma vitamin C and vitamin E were measured with high performance liquid chromatography using ultraviolet and fluorescent detection 26, 27 in plasma. For vitamin C, plasma extracts were treated with metaphosphoric acid at the point of collection and were then snap frozen with dry ice. Laboratory-blinded split samples were used to ensure quality control throughout the study. Data on vitamin C were available in 3788 men, and data on vitamin E were available in 3718 men.
Follow-Up
All men have been followed up from initial examination (1978) (1979) (1980) for cardiovascular morbidity, 28 and follow-up has been achieved for 99% of the cohort. In the present analyses, all-cause mortality and morbidity events are based on follow-up from reexamination in 1998 to 2000 at mean age 60 to 79 years to June 2010. Survival times were censored at date of HF, death from any cause or end of the study follow-up period (June 2010), whichever occurred first. Information on death was collected through the established tagging procedures provided by the National Health Service registers. Fatal CHD events were defined as death with CHD (International Classification of Diseases 9th revision, codes 410-414) as the underlying code. A nonfatal MI was diagnosed according to World Health Organization criteria. Evidence of nonfatal MI and HF was obtained by ad hoc reports from general practitioners supplemented by biennial reviews of the patients' practice records (including hospital and clinic correspondence) through to the end of the study period. Incident CHD included fatal CHD and nonfatal MI. Incident nonfatal HF was based on a doctor diagnosis of HF from primary care records and confirmed by a clinical record review by the research team. Incident HF included incident nonfatal HF as well as death from HF (International Classification of Diseases 9th revision, code 428). Men with pre-existing MI were defined as those with a history of doctor-diagnosed MI at examination (1998-2000) based on patient recall and general practitioner's record.
Statistical Methods
The distribution of plasma vitamin C and dietary vitamin E was positively skewed, and log transformation was used. Cox proportional hazards model was used to assess the multivariate-adjusted hazards ratio (relative risk) in a comparison of quartiles of plasma and dietary vitamins C and E and for 1 SD increase in the log of these measures. In multivariate analyses, smoking (never, longterm ex-smokers (>15 years), recent ex-smokers (<15 years), and current smokers), social class (manual versus nonmanual), physical activity (4 groups), alcohol intake (non-, occasional, light, moderate, and heavy defined as >6 drinks/d), diabetes mellitus (yes/no), use of antihypertensive treatment (yes/no), left ventricular hypertrophy (yes/no), and atrial fibrillation (yes/no) were fitted as categorical variables. Systolic blood pressure, HDL-C, FEV 1, CRP, and NT-proBNP were fitted continuously. To evaluate whether vitamin C predicted HF independent of incident CHD during follow-up, we adjusted for incident CHD by fitting CHD as a time-dependent covariate. Analyses were performed separately in men with and without pre-existing MI. To assess the association between plasma vitamin E and HF, we examined the association between absolute levels of plasma vitamin E as well as standardized vitamin E in relation to HF risk. Standardized vitamin E was expressed as the ratio of vitamin E to total cholesterol. 29 A 2-sided P<0.05 was accepted as statistically significant for all analyses. No adjustment for multiple comparisons was made.
Results
During the mean follow-up period of 11 years, there were 263 cases with incident HF (7.3/1000 person-years) in the 3919 men with no diagnosed HF. Men with pre-existing MI (n=393; 64 cases) had significantly higher HF rates than men without pre-existing MI (n=3526; 199 cases; 20.4 versus 5.9/1000 person-years; P<0.0001). The geometric mean level (interquartile range) of plasma vitamin C in the study population was 21.8 (14.1-39.60) mmol/L, and the mean (SD) level of plasma vitamin E was 33.3 (11.9) mmol/L. Mean levels of plasma vitamin C and vitamin E were similar in men with and without pre-existing MI. Mean dietary vitamin C intake was 82.6 (37.1) mg, and mean (interquartile range) dietary vitamin E was 7.3 (5.1-10.4) mg. The correlation between plasma vitamin C and dietary vitamin C was r=0.26 (P<0.0001), and the correlation between plasma vitamin E and dietary vitamin E was r=0.10 (P<0.0001). These correlations were similar in both men with and without pre-existing MI. Tables 1 and 2 show characteristics in the study population by quartiles of plasma vitamin C and vitamin E. Plasma vitamin C was inversely associated with many CV risk factors, including hypertension, adiposity, heart rate, HDL-C, GGT, estimated glomerular filtration rate, FEV 1 , CRP, von Willebrand factor, and NT-proBNP. By contrast, plasma vitamin E levels were positively associated with many CV risk factors, including blood lipids and blood pressure, although no association was seen between plasma vitamin E and CRP, von Willebrand factor, or NT-proBNP. AF indicates atrial fibrillation; BMI, body mass index, CHD, coronary heart disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GGT, γ-glutamyl transferase; HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; LVH, left ventricular hypertrophy; MI, myocardial infarction; NT-proBNP, N-terminal pro-brain natriuretic peptide; SBP, systolic blood pressure; and vWF, von Willebrand factor.
Baseline Characteristics by Quartiles of Vitamin C and Vitamin E
Mean and SD; *Geometric mean and interquartile range.
Plasma Vitamin C and Incident HF
The Figure shows the Kaplan-Meier estimates of the cumulative incidence of HF by quartiles of vitamin C in men with and without pre-existing MI. In both men with and without pre-existing MI, higher plasma high vitamin C (top quartile) was associated with a significant reduction in risk of incident HF compared with those in the lowest quartile even after adjustment for age, smoking, physical activity, social class, antihypertensive treatment, systolic blood pressure, HDL-C, estimated glomerular filtration rate, heart rate, prevalent diabetes mellitus, and left ventricular hypertrophy (Table 3) . The reduced HF risk associated with elevated plasma vitamin C remained even after further adjustment for lung function, CRP, and von Willebrand factor and was statistically significant in those without pre-existing MI. Among men with pre-existing MI, the association was of similar strength, although of marginal statistical significance. This is likely to be attributable to the lack of power because of the smaller number of men in this subgroup. AF indicates atrial fibrillation; BMI, body mass index, CHD, coronary heart disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GGT, γ-glutamyl transferase; HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; LVH, left ventricular hypertrophy; MI, myocardial infarction; NT-proBNP, N-terminal pro-brain natriuretic peptide; SBP, systolic blood pressure; and vWF, von Willebrand factor.
Mean and SD; *geometric mean and interquartile range.
Plasma Vitamin E and Incident HF
In contrast, vitamin E showed no association with risk of HF in men with or without MI. Similarly no association was seen when examined in relation to the vitamin E cholesterol ratio (P=0.22 and P=0.93 for trend) in men with and without MI.
Dietary Vitamin C and E and Incident HF
Dietary intake of vitamin C showed no association with risk of HF in men with or without MI ( 
Discussion
In this study of older British men free of HF, plasma vitamin C but not plasma vitamin E was associated with reduced risk of HF, both in men with and without pre-existing MI. No association was seen between dietary intake of vitamin C (reflecting reported fruit and vegetable intake) and risk of HF. However, increased dietary intake of vitamin E (α-tocopherol) was associated with significantly increased risk of HF in those with no pre-existing MI, supporting previous antioxidant trials in HF, suggesting an adverse effect of vitamin E on HF. 11, 12 Our finding on plasma vitamin C confirms a recent report of a potential beneficial effect of plasma vitamin C on HF risk in men and women with no established CVD 17 and suggests that benefit extends to both older adults with and without pre-existing MI. We were able to explore a wider range of novel risk markers not previously assessed, including cardiac marker NT-proBNP and markers of endothelial dysfunction (von Willebrand factor) in the vitamin C-HF association.
Vitamin E and HF
Trials on vitamin E supplements (α-tocopherol) and CVD risk have generally observed no overall reduction in risk of CVD events. 6, 7, 10 Primary prevention trials, including the Physician's Health Study II and the Women's Health Study, observed no increase in risk of HF with vitamin E supplements. 6, 10 However, in the present study, we observed an association between higher dietary vitamin E intake and HF risk. Although this could reflect the influence of confounding, we have taken into account the influence of many potential confounders, including lifestyle characteristics, diabetes mellitus, hypertension, and vitamin supplement use. Moreover, recent secondary prevention trials have yielded similar positive associations between vitamin E intake and HF. 11, 12 The reason for an increased risk of HF in this study of older men is not clear, but it may relate to the suggestion that α-tocopherol may become a pro-oxidant in a pre-existing environment with increased oxidative stress, thereby depressing myocardial function. This would be true in older populations in whom subclinical atherosclerosis is highly prevalent and who tend to have increased oxidative stress levels. 30 There is also evidence that α-tocopherol may suppress other fat soluble antioxidants, such as γ-tocopherol, which is considered a more powerful antioxidant than α-tocopherol, disrupting the natural balance of antioxidant systems and increasing vulnerability to oxidative damage. 31 In contrast to dietary vitamin E, we observed no association between plasma vitamin E and risk of heart failure. Dietary vitamin E and plasma vitamin E correlated poorly in this study (r=0.10) as has been shown in other studies. 32 It is well established that plasma concentrations of vitamin E increase with the amount of total plasma lipids, 29 and particularly with LDL-cholesterol, the principal carrier of tocopherol in the circulation, as was seen in this study. Thus, vitamin E absorption may be influenced by factors other than diet and seems to be an unreliable marker of dietary vitamin E (α-tocopherol) intake. This may explain the differences in association between dietary and plasma vitamin E and HF in the present study.
Vitamin C and HF
In contrast with our findings for vitamin E, plasma vitamin C was associated with a significant reduction in risk of HF in both men with and without pre-existing MI. The inverse association Figure. Kaplan-Meier curves of cumulative heart failure (HF) incidence by quartiles of vitamin C in men without and with preexisting myocardial infarction (MI). Log-rank test: men without MI, P=0.0006; men with MI, P=0.03. Plasma vitamin C, but not vitamin E, is associated with reduced risk of HF in older men. July 2013 between plasma vitamin C and HF in men without MI was not explained by traditional risk factors for HF, lung function, endothelial dysfunction, inflammation, or NT-proBNP (a marker of cardiac function) and was seen after taking into account incident MI during follow-up. In those with pre-existing MI, the beneficial effect seemed to be associated to some extent with its favorable effect on inflammation, lung function, and endothelial function. A possible mechanism for the beneficial effect of plasma vitamin C on HF may relate to the fact that vitamin C enhances arterial dilation through its effect on nitric oxide release. 33 Although many trials on vitamin C supplements and CVD have been disappointing, most have focused on overall CVD or CHD as the primary end point. The association between vitamin C and HF seems to involve plasma vitamin C rather than dietary vitamin C, a finding similar to that observed in the EPIC (European Investigation into Cancer and Nutrition) Norfolk study. 34 The correlation between plasma vitamin C and dietary intake of vitamin C in this study, although significant, was weak (r=0.26), but was similar to that observed in the EPIC Norfolk study (r=0.28). 34 Although the low correlations between dietary vitamin C and plasma levels may partly reflect the inaccuracy of dietary questionnaires in the assessment of vitamin C intake, it may also reflect the influence of variation in vitamin C absorption and metabolism, which is partly genetically controlled, 35 on plasma vitamin C levels.
Strengths and Limitations
Our study is not without some limitations. It was based on an older predominantly white male population of European extraction, so that the results cannot be generalized directly to women, younger populations, or other ethnic groups. The current findings are based on doctor-diagnosed HF, which is likely to underestimate the true incidence of HF in this study population. However, the determinants of HF in this study population (including obesity) 19 generally accord with previous data and, therefore, suggest potential external validity for our findings. Echocardiographic measurements were not performed in the present study and, therefore, we were not able to differentiate systolic and diastolic Data on vitamin C (n=3818); data on vitamin E (n=3741); 1 SD log vitamin C=0.89. Quartile 1 used as the reference group. Model 1 adjusted for age, smoking, social class, alcohol intake, physical activity, body mass index, high-density lipoprotein cholesterol, diabetes mellitus, use of antihypertensive drugs, systolic blood pressure, estimated glomerular filtration rate, left ventricular hypertrophy, and heart rate. Model 2 adjusted for model 1 and FEV 1 , C-reactive protein, and von Willebrand factor. CI indicates confidence interval; HF, heart failure; and MI, myocardial infarction.
HF. Although the present study was a prospective observational study and not a randomized trial, the association between vitamin C and HF seemed independent of confounding factors.
Conclusion
Plasma vitamin C, but not vitamin E, is associated with reduced risk of HF in both men with and without pre-existing MI. High intake of dietary vitamin E seems to be associated with increased risk of HF in older men. Primary intervention trials in older people at risk of HF are needed to confirm whether increasing plasma vitamin C levels through supplements or diet would reduce risk of HF.
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